Drug intelligence / Profile preview

EDP172

Development stage: Preclinical
Lead developer: EddingGenor Pharmaceutical Group
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

EDP172 is a dual-targeting small interfering RNA (siRNA) therapeutic being developed by Genor Biopharma for the treatment of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). The drug is designed to simultaneously silence two distinct genetic targets involved in lipid metabolism or cardiovascular risk reduction, utilizing the RNA interference (RNAi) pathway to degrade messenger RNA (mRNA) transcripts and prevent the translation of proteins that contribute to elevated lipid levels. EDP172 is part of Genor Biopharma's oligonucleotide platform, which focuses on cardiometabolic and liver diseases.

Beyond the preview

Go deeper on EDP172.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDP172.